Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study of the Safety of Trogarzo Administered as an Undiluted "IV Push" Over a Reduced Interval in Clinically Stable HIV-1 Infected Trogarzo Experienced Patients

Next Previous
X
Search
Trial Profile

A Phase 3 Study of the Safety of Trogarzo Administered as an Undiluted "IV Push" Over a Reduced Interval in Clinically Stable HIV-1 Infected Trogarzo Experienced Patients

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Apr 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibalizumab (Primary) ; Ibalizumab (Primary) ; Ibalizumab
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics; Registrational
  • Sponsors TaiMed Biologics

    • Most Recent Events

    • 06 Mar 2024 Results assessing the safety and efficacy of IV and IM administration of Ibalizumab for the treatment of HIV-1 infection in heavily treatment experienced (HTE) people with HIV, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
    • 28 Feb 2024 According to a Theratechnologies media release, the FDA has issued a refusal to file letter (RTF) to a supplemental Biologics License Application (sBLA) filed by Theratechnologies Inc. for an intramuscular (IM) method of administration for maintenance dosing of Trogarzo (ibalizumab-uiyk). The RTF followed a preliminary review of sBLA by FDA, which found that application did not include data agency required to establish a pharmacokinetic bridge between IM and IV administration.
    • 02 Jan 2024 According to a Theratechnologies media release, the Company has filed a supplemental Biologics License Application (sBLA) for an IM method of administration for the maintenance dose of Trogarzo to the United States Food and Drug Administration (FDA) for review. In accordance with the FDAs filing review period, Theratechnologies expects to receive an acknowledgment letter of the sBLA application within 30 days along with a PDUFA goal date

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top